Neuroprotective Agents: Therapeutic Applications and Global Markets
The global market for neuroprotective agents will grow from $54.4 billion in 2017 to $75.8 billion by 2022 with a compound annual growth rate (CAGR) of 6.8% for the period of 2017-2022.
- 39 tables
- An overview of the global market for neuroprotective agents and their therapeutic applications
- Analyses of global market trends, with data from 2016, 2017, and projections of compound annual growth rates (CAGRs) through 2022
- Market breakdowns by indication, mechanism of action, and by region
- Discussion of various neurodegenerative disorders
- Profiles of key companies in the market, including Bayer Healthcare, Eisai Inc., Glaxosmithkline Plc, Merck Serono S.A., Novartis Ag and Teva Pharmaceutical Industries Ltd.
The scope of this report covers the global market for small molecule drugs, monoclonal antibodies, gene and cell therapies, and other biotechnology products that are approved or being developed for the treatment of neurological disorders.
Therapeutic indications are grouped under four categories: cerebrovascular diseases, neurodegenerative disorders, ophthalmic diseases and traumatic CNS injuries. Indication subcategories include stroke, Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, multiple sclerosis, Huntington’s disease, spinal muscular atrophy, epilepsy, glaucoma, age-related macular degeneration, optic neuropathies, diabetic retinopathy and traumatic brain and spinal cord injuries. The report does not cover the neuroprotective agents that are used for protecting the brain during risky neurosurgeries and other general operations.
Ufuk Ezer. Ezer holds a bachelor's degree in bioengineering and a master's degree in biotechnology, bioprocessing and business management. He possesses extensive pharmaceutical research and development experience and has participated in projects for various international institutions and organizations. Ezer has been granted scholarships and awards during his post-study works in countries such as Japan and Panama based on the high quality of his work and excellence in the fields of research.